- Home
- CATX vs DHF Comparison
CATX vs DHF Comparison
Compare CATX & DHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CATX | DHF |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.1M | 185.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CATX | DHF |
|---|---|---|
| Price | $2.74 | $2.49 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $11.56 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 451.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.65% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,075,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $2.06 |
| 52 Week High | $5.39 | $2.39 |
Technical Indicators
Market Signals| Indicator | CATX | DHF |
|---|---|---|
| Relative Strength Index (RSI) | 53.90 | 46.83 |
| Support Level | $2.67 | $2.46 |
| Resistance Level | $2.88 | $2.49 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 64.44 | 42.86 |
Price Performance
Historical ComparisonAbout CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
About DHF BNY Mellon High Yield Strategies Fund
BNY Mellon High Yield Strategies Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income and its secondary objective is capital appreciation. The fund invests predominantly in fixed-income securities of below-investment-grade credit quality.